Evotec's Leadership Shakeup Confronts a Challenging Financial Reality

Evotec appoints new CCO and Chairman to boost sales, but 2025 profit relied on a one-off gain. Core drug discovery business is struggling as the firm enters a difficult transition year.

The Hamburg-based drug discovery firm Evotec SE is bringing in heavyweight industry veterans to steer its commercial future, even as its latest financial results reveal a business propped up by one-off gains. The company announced the appointment of Dr. Ashiq H. Khan as its new Chief Commercial Officer, a manager credited with overseeing deals worth over $7 billion in his career. Simultaneously, Dieter Weinand, a veteran of Pfizer and Sanofi, is nominated to become Chairman of the Supervisory Board starting in June.

This high-profile personnel offensive aims to revitalize global sales, but it lands against a backdrop of stark operational challenges. For the full year 2025, Evotec reported revenue of EUR 788.4 million and an adjusted EBITDA of EUR 41.1 million, hitting the upper end of its own forecast. However, this seemingly solid performance was almost entirely due to a one-time EUR 65 million license payment from the Sandoz transaction. Strip out that special effect, and the company would have posted an operating loss for the year.

The internal disparity between business units is pronounced. The biologics manufacturing division, Just – Evotec Biologics, is emerging as the group's sole robust growth engine. It delivered revenue of EUR 259.4 million and a strong EBITDA of EUR 53.2 million. In stark contrast, the core drug discovery business is struggling, with revenue there plunging 13.5 percent and the segment's operating result sinking to a loss of EUR 12.0 million, exposing significant underutilization of research platforms.

With such milestone payments absent in the current year, management is bracing for a difficult transition. CEO Mario Polywka has declared 2026 a "classic transition year," guiding for revenue to stagnate between EUR 700 million and EUR 780 million and projecting a meager operating profit of up to EUR 40 million. Analysts are even more pessimistic, forecasting a net loss of approximately EUR 67.5 million for the full year.

The company's ongoing "Horizon" restructuring program, which will consolidate global sites to ten, is central to its recovery plan. Management targets cost savings of EUR 75 million by the end of 2027, with the first effects expected to appear in the second half of 2026. The stock market reflects deep skepticism about the near-term path. Trading at EUR 4.53, the share has lost roughly 18 percent since the start of the year and remains well below its 50-day moving average of EUR 5.25.

Despite the bleak short-term outlook, some investors are positioning for a long-term payoff. Activist investor MAK Capital, which holds about 7 percent of shares, continues to push for a separate stock market listing of the US-based Just – Evotec Biologics unit. Hedge fund Marshall Wace LLP recently used the depressed share price to build a position. Analysts at RBC Capital Markets maintain a price target of EUR 10, pointing to yet-unpriced upfront payments from the Tubulis transaction as potential catalysts.

The coming months represent a critical test. Evotec's new leadership must prove that drastic cost cuts are taking hold and that they can successfully commercialize the company's pipeline. Structural improvements promised for the latter half of 2026 must materialize to alleviate pressure from activists and justify the ambitious long-term goal of breaking the EUR 1 billion revenue mark by 2030.